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Abstract
Background—There has been an increase in the use of pulmonary artery (PA) catheters in heart 
failure (HF) in the United States in recent years. However, patterns of hospital-use and trends in 
patient outcomes are not known.
Methods and Results—In the National Inpatient Sample 2001–2012, using ICD-9 codes we 
identified 11,888,525 adult (≥18 years) HF hospitalizations nationally, of which an estimated 
75,209 (SE 0.6%) received a PA catheter. In 2001, the number of hospitals with ≥1 PA 
catheterization was 1753, decreasing to 1183 in 2011. The mean PA catheter use per hospital 
trended from 4.9/year in 2001 (limits 1–133) to 3.8/year in 2007 (limits 1–46), but increased to 
5.5/year in 2011 (limits 1–70). During 2001–2006, PA catheterization declined across hospitals; 
however, in 2007–2012 there has been a disproportionate increase at hospitals with large bedsize, 
teaching programs, and advanced HF capabilities. The overall in-hospital mortality with PA 
catheter use was higher than without PA catheter use (13.1% vs. 3.4%, P<0.0001), however, in 
propensity-matched analysis, differences in mortality between these groups have attenuated over 
time – risk-adjusted odds ratio for mortality for PA-catheterization, 1.66 (95% CI 1.60–1.74) in 
2001–2003 down to 1.04 (95% CI 0.97– 1.12) in 2010–2012.
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Conclusions—There is substantial hospital-level variability in PA catheterization in HF along 
with increasing volume at fewer hospitals overrepresented by large, academic hospitals with 
advanced HF capabilities. This is accompanied by a decline in excess mortality associated with PA 
catheterization.
Keywords
heart failure; resource utilization; catheterization; variation
Pulmonary artery (PA) catheters have been traditionally used for invasive bedside 
hemodynamic monitoring in heart failure (HF) both to guide treatment decisions and to 
evaluate the hemodynamic responses to various therapies such as intravenous diuretics, 
vasodilators, and inotropes.1–3 While early data on efficacy of invasive hemodynamic 
monitoring with PA catheter in HF were encouraging,4–6 the ESCAPE trial, a large 
randomized trial evaluating PA catheterization in routine HF care published in October 
2005, provided evidence against their utility in the routine management of HF.7 The current 
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines 
support the use of PA catheter in HF patients with cardiogenic shock or with respiratory 
failure requiring mechanical ventilation (Class IA). Routine use of PA catheter for 
management of acute HF is not recommended (Class III).8 However, despite these 
recommendations, we recently reported a significant increase in the use of PA catheters in 
HF hospitalization in the United States over the past few years, particularly in patients 
without cardiogenic shock or respiratory failure.9 The hospital- and patient-level factors 
underlying this temporal increase in PA catheter use in HF are not well understood. 
Furthermore, with significant advances in the management of HF in recent years, changes in 
utilization of PA catheterization in HF care and its association with clinical outcomes in not 
known. Against this background, we aim to evaluate hospital variation, temporal trends, and 
factors associated with PA catheter use in HF care and assess its association with patient 
outcomes over time.
METHODS
Data sources
We used the National Inpatient Sample (NIS), the largest all payer database of hospitalized 
patients in the United States, which is managed under the Healthcare Cost and Utilization 
Project by the Agency for Healthcare Research and Quality.10 It is provided as an annual 
data set comprised of a 20% sample of all inpatient hospitalizations drawn from 
participating states in a given year and consists of de-identified data on demographics, 
admission diagnoses, procedures, comorbidities and outcomes of hospitalization. We 
included data for years 2001 through 2012 in our study.
The design of NIS has been described in previous studies.11, 12 During 2001–2011, the NIS 
was constructed by including 100% of acute inpatient hospitalizations from a 20% random 
sample of all reporting hospitals stratified by bed-size, teaching status and location. Patient 
admissions under an observational status and those from rehabilitation hospitals, long-term 
non–acute care hospitals, psychiatric hospitals, and chemical dependency units were not 
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included. In 2012, the NIS was redesigned to include a random 20% sample of patient 
discharges selected from 100% of the participating hospitals in 2012, with all discharges 
stratified by hospital bed-size, teaching status and location.13, 14 Moreover, compared to 
2001–2011 when hospitals were identified using the American hospital association survey, 
the hospital systems in 2012 were identified using the state inpatient database (SID). The 
changes to the NIS 2012 improved the precision of national discharge estimates. To account 
for changes in sampling methodology a revised set of discharge weights were provided, 
called ‘trend weights’ to be use for all studies spanning 2012.13 We used the provided trend 
weights for all patient-level analyses. However, since only 20% of discharges from sampled 
hospitals were available for the year 2012, as opposed to 100% hospital discharge volume in 
2001–2011, hospital-level estimates which relied on census of hospital discharges for a 
given year were limited to years 2001–2011. Further details are available in HCUP’s NIS 
redesign report.13
Study Population & Variables
The NIS provides patient- and hospital-level information on each patient discharge, 
including patient demographics (including age, sex, race, etc.), primary and up to 24 
secondary discharge diagnoses, and a maximum of 15 procedures performed during the 
index hospitalization. The information on both diagnoses and procedures is available as 
International Classification of Diseases – 9th Clinical Modification (ICD-9) codes as well as 
their validated combinations into broad categories, the Clinical Classification of Diseases 
Software (CCS) codes developed by Elixhauser et al.15 We used a combination of ICD-9 and 
CCS codes to identify specific comorbidities and procedures. Using the provided hospital 
identification number, each hospitalization was linked to corresponding hospital 
characteristics, including bed strength, teaching status, urban vs. rural location and hospital 
census region.
We identified all adults (>18 years) admitted with a primary discharge diagnosis of heart 
failure (HF) using ICD-9 codes 428.x, 402.x1, 404.x1, and 404.x3 which have been 
previously validated and used to identify heart failure hospitalization in the American Heart 
Association’s Get With The Guidelines (GWTG) – Heart Failure registry and administrative 
databases.16, 17 We then identified patients admitted for HF who underwent placement of a 
pulmonary artery catheter using the ICD-9 codes 89.63 (pulmonary artery pressure 
monitoring), 89.64 (pulmonary artery wedge monitoring), 89.66 (measurement of mixed 
venous blood gases), 89.67 (monitoring of cardiac output by oxygen consumption technique 
[Fick method]) and 89.68 (monitoring of cardiac output by other technique [thermodilution 
indicator]) used in prior studies.18
In order to limit our analysis to use of PA catheters in the management of HF, we excluded 
hospitalizations where the reported PA catheter may have been used for an alternative 
indication. First, to exclude patients where the recorded PA catheter may have been used for 
operative monitoring, we excluded patients who underwent any major surgical procedure 
during the index hospitalization, as done previously.18 For this, surgery flag software 
developed by HCUP were used to identify if any of the listed procedures on a patient record 
represented major invasive procedures, defined as “an invasive therapeutic surgical 
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procedure involving incision, excision, manipulation, or suturing of tissue that penetrates or 
breaks the skin; typically requires use of an operating room; and also requires regional 
anesthesia, general anesthesia, or sedation to control pain”. All hospitalization with ≥1 of 
these procedures were excluded. Second, to exclude patients who may have undergone 
placement of PA catheter during emergent management of hemodynamic instability, we 
excluded patients who also underwent placement of a temporary cardiac assist device (e.g. 
intra-aortic balloon pump, percutaneous ventricular assist devices) during the index 
hospitalization. Using our exclusion criteria above, we excluded 3443 cases (weighted N = 
16,532) from our study.
Statistical analysis
First, we compared patient characteristics for those with vs. without PA catheter use during a 
HF hospitalization. Second, for each study-year we identified hospitals using ≥1 PA 
catheters in a HF hospitalization. Since 100% of the discharge volume for each included 
hospital in a year was included in the sample for years 2001–2011, analysis of hospital PA 
catheter volume was limited to these years. To describe hospital-level variability in PA 
catheter utilization, we examined proportion of HF admissions with PA catheter use at 
hospitals with >10 HF admissions for the most recent year with complete hospital data 
(2011). For this analysis, HF admissions were further stratified by HF with class I 
indications for PA catheter use (cardiogenic shock, respiratory failure requiring mechanical 
ventilation) and HF without these indications.
Next, to better understand the hospital-level variation in use of PA catheters over time, we 
assessed the temporal trend in the proportion of hospitals using 1 or more PA catheters in a 
HF hospitalization and the mean PA catheter volume per hospital during the study period. 
Furthermore, we also compared the trends in PA catheter use over time across different 
hospital subgroups available in the HCUP hospital dataset, defined by hospital bedsize, 
teaching status, and urban vs. rural location. Bedsize designations (small, medium or large) 
were based on defined cutoffs specific for the hospital’s location and teaching status.19 
Teaching hospitals were defined by a ratio of ≥0.25 of full-time equivalent interns/residents 
to non-nursing home beds.20 Urban vs. rural status were assigned based on the census 
designation of the geographical location of the hospital.21 We further identified hospitals as 
advanced HF centers if they performed ≥1 LVAD implantation or heart transplantation in a 
given year. Temporal trends were further assessed in the years before (2001–2006) and after 
(2007–2012) the ESCAPE trial.
As recommended by the AHRQ, we performed all analyses using a survey methodology 
while accounting for clustering and stratification of patients. For comparative and subgroup 
analysis, we used domain analysis to ensure that the estimated population statistics and 
measures of variance are accurate.22 Trend analysis was performed using the Cochran-
Armitage test for categorical variables and survey-specific linear regression for continuous 
variables. Subgroup comparisons were tested with the Rao-Scott chi-square test for 
categorical variables and survey ANOVA test for continuous variables.
Next, we examined predictors of PA catheter use at hospitals across the US. For this, we 
performed survey-specific logistic regression analysis with PA catheter use as a dependent 
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variable and patient and hospital characteristics as independent predictor variables. Patient 
characteristics included in the model were demographics, discharge diagnoses, comorbidity 
burden (using the Charlson Comorbidity Index [CCI] score), comorbidities (like diabetes, 
hypertension, etc.) and inpatient procedures (mechanical ventilation and vasopressor use). 
Hospital characteristics included advanced HF facility, teaching status, bedsize, rural-urban 
location and geographic region.
Last, we assessed for the association of PA catheter use with in-hospital mortality. For this, 
we first compared differences in patient characteristics and unadjusted outcomes for patients 
with and without PA catheter use when admitted for HF to hospitals using at least 1 PA 
catheter in HF patients in a given year. To account for confounding by indication, we 
performed propensity-matched analysis comparing HF patients with vs. without PA catheter 
use. We first created a non-parsimonious logistic regression model to calculate each patient’s 
propensity (or likelihood) of receiving a PA catheter based on his/her clinical characteristics. 
The variables included in our model were patient age, sex, secondary cardiovascular 
diagnoses (cardiogenic shock, cardiac arrest, AMI, coronary artery disease, peripheral artery 
disease, cerebrovascular disease, valvular heart disease, cardiac arrhythmia and conduction 
disorders), comorbid conditions (hypertension, diabetes, dyslipidemia, cancer, liver disease, 
chronic kidney disease, acute kidney injury, fluid-electrolyte disorder, chronic obstructive 
pulmonary disease, coagulopathy, tobacco abuse and substance-use disorder), CCI score, 
procedures (mechanical ventilation and vasopressor use) and nature of admission (non-
elective vs. elective). In addition to the variables above we included the trend weight in 
estimation of the propensity score above as recommended for propensity-matched in studies 
with a survey design.
Using the propensity scores calculated above, we performed 1:2 matching between HF 
patients with PA catheter use and those without PA catheter use. Each selected patient with 
PA catheter use (case) was first matched with as many patients without PA catheter use 
(controls) whose propensity scores were within the pre-specified caliper width of one-
quarter of the standard deviation of the logit of the propensity score of the case. Cases 
without any corresponding matched controls were excluded at this step. To further select 
controls that were the closest match to a selected case, we chose those two controls with 
smallest value of the Mahalanobis metric for the case. The Mahalanobis metric measures the 
degree of closeness between 2 observations and is their multivariate distance based on the 
mean, variance and the covariance of the pre-specified variables.23, 24 Mahalanobis metric 
was calculated using pre-specified characteristics - age, presence of cardiogenic shock, 
ventilator use and AMI.23 To test the success of our matching algorithm in achieving 
covariate balance, we calculated standardized differences between case and control groups 
for all covariates in our model before and after matching. A standardized difference of <10% 
for all covariates after matching is indicative of a successful match.25 We used the Cochran–
Mantel–Haenszel test for matched data to compare the association of PA catheter use with 
in-hospital mortality and included the discharge weight in the analysis to account for the 
survey nature of our data.
To account for temporal changes in HF outcomes, we performed the propensity-matched 
analysis after dividing patients into four separate 3-year cohorts – 2001–2003, 2004–2006, 
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2007–2009 and 2010–2012. Within each cohort, we matched each HF patient receiving a PA 
catheter in a given cohort (‘case’) to two covariate-matched HF patients without PA catheter 
use from within the same cohort (‘controls’). Second, we performed sensitivity analyses to 
assess the associations of PA catheter use on the outcomes in patients without a class I 
indications for use in HF, which included patients without cardiogenic shock or use of 
mechanical ventilation in the index hospitalization. We compared their outcomes using 1:2 
propensity-matched analysis in the four separate time periods, similar to the one described 
above.
The level of significance was set at a P value of 0.05. All analyses were performed using 
SAS 9.4 software (SAS institute, Cary, NC), including SAS PROC SURVEYMEANS and 
PROC SURVEYFREQ for analysis of complex survey data. The study was reviewed by the 
University of Iowa Institutional Review Board (IRB), which exempted the study from IRB 
approval and waived the requirement for informed consent since it uses previously collected 
de-identified data.
Post-hoc analyses
Based on reviewer comments, we performed additional analyses. First, we examined for 
rates of reported complications –periprocedural bleeding (ICD-9 codes 998.11-998.12) and 
iatrogenic pneumothorax (ICD9 code 512.1), which are relevant for patients undergoing PA 
catheterization. Next, we compared mortality and complication rates with PA catheter use in 
HF by hospital subgroups. Finally, to assess if our selection criteria affected trends, we 
repeated the analyses of trends in hospital PA catheter utilization after including all patients 
with a primary diagnosis of HF without excluding any subgroups.
RESULTS
In 2001 through 2012 we identified 2,492, 284 admissions in the NIS with a primary 
discharge diagnosis of HF, without any major surgical intervention or use of a mechanical 
circulatory support device during the index hospitalization, which estimates to 11,888,525 
HF hospitalizations nationally over the 12-year period. Of these, 15,786 patients or an 
estimated 75,209 (0.6%) underwent placement of a PA catheter during the index 
hospitalization. Patients who received a PA catheter appeared to differ substantially from 
other patients hospitalized for HF (Table). At hospitals with at least 1 PA catheter placement 
in HF patients in a given year, patients receiving a PA catheter were younger; more 
commonly men; and more likely to have cardiogenic shock, AMI, cardiac arrest, require 
mechanical ventilation as compared with patients who did not undergo PA catheterization. 
Prevalence of comorbid conditions like hypertension, diabetes, malignancies, and COPD 
were lower in HF patients with vs. without PA catheter use.
The number of hospitals using at least 1 PA catheter for a HF hospitalization dropped 
consistently, from an estimated 1753 hospitals in 2001 to 1183 hospitals in 2011 (Figure 1). 
PA catheter use varied across hospitals, with a mean volume of 15.0/1000 HF 
hospitalizations in 2001 (limits: 1.0 – 333.3/1000 HF, 10th centile – 2.6/1000 HF; 90th 
centile 30.0/1000 HF), which decreased to 11.9/1000 HF (limits: 1.1 to 407.4/1000 HF, 10th 
centile – 2.3/1000 HF; 90th centile 19.9/1000 HF) in 2007, increasing slightly to 12.5/1000 
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HF (limits: 0.9 to 190.5/1000 HF, 10th centile – 1.9/1000 HF; 90th centile 25.9/1000 HF) in 
2011 (Supplemental Figure 1). During this period mean HF admissions/hospital decreased 
from 413/year in 2001 to 394/year in 2007, increasing thereafter to 475/year in 2011 
(Supplemental Figure 2). Overall, the mean PA catheter use per hospital trended down from 
4.9/year in 2001 (limits 1–133) to 3.8/year in 2007 (limits 1–46), but increased to 5.5/year in 
2011 (limits 1–70) (Supplemental Figure 3). The utilization of PA catheterization varied 
across hospitals for HF admissions with and without class I indications (cardiogenic shock 
or respiratory failure) for their use (in 2011 for hospitals >10 HF, class I: mean 63/1000 HF, 
limits: 5 – 375/1000 HF; and non-class I: mean 10/1000 HF, limits: 0 – 195/1000 HF, 
Supplemental Figure 4).
The temporal trends in use of PA catheter varied across different hospital subgroups. There 
was a significant decline in use of PA catheter in the pre-ESCAPE era across all hospital 
groups. However, in the post-ESCAPE era, we observed a significant increase in use of PA 
catheter over time among large bed-size hospitals vs. small or medium size hospitals (Figure 
2A), teaching hospitals vs. non-teaching hospitals (Figure 2B), urban centers vs. rural 
centers (Figure 2C), and advanced HF centers vs. non-advanced HF centers (Figure 2D).
In a stratified multivariable model, patient-level factors independently associated with higher 
PA catheter use were young age, female sex, elective admission, admission with AMI, 
cardiogenic shock, respiratory failure requiring mechanical ventilation, acute kidney injury, 
and valvular heart disease (Figure 3). Hospital characteristics independently associated with 
higher PA catheter use were advanced HF facilities and teaching status.
Patients undergoing PA catheterization in a HF hospitalization had higher mortality rates 
(13.1% vs. 3.4%) and length of stay (9.9 days vs. 5.1 days) compared to those without PA 
catheter use. Mean length of stay decreased modestly from 10.4 to 9.4 days over the study 
years and mortality rate decreased substantially from 22.1% in 2001 to 6.9% in 2012. After 
risk adjustment, temporal trends in mortality continued to be significant (Figure 4A). In 1:2 
propensity-matched analyses (Supplemental Figure 5), the risk-adjusted mortality in the PA 
catheter group was higher than the non-PA catheter group, but the magnitude of difference in 
mortality attenuated over time, with risk-adjusted odd ratio (OR) for mortality with PA 
catheter use 1.66 (95% C.I. 1.60 – 1.74) in 2001–2003 to risk-adjusted OR 1.04 (95% C.I. 
0.97 – 1.12) in 2010–2012 (Figure 4B). Similar findings were also observed in sensitivity 
analysis limited to HF patients without cardiogenic shock or use of mechanical ventilation 
(Supplemental Figure 6).
In post-hoc analyses, rates of reported periprocedural bleeding and iatrogenic pneumothorax 
were low (≤1%, Supplemental Table 1); and complications, as well as in-hospital mortality 
did not differ consistently between various hospital subgroups (Supplemental Tables 2–5). 
Finally, in sensitivity analyses that included all HF admissions, trends in number of hospitals 
with PA catheter use (Supplemental Figure 7), and average PA catheter utilization – both 
overall (Supplemental Figure 8) and across hospital subtypes (Supplemental Figure 9) – 
were consistent with the primary analyses.
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DISCUSSION
We observed several important findings in the present study. First, we observed significant 
hospital-level variation in the utilization of PA catheterization in HF. Second, while there has 
been a temporal increase in the utilization of PA catheters in HF, this increase appears to be 
confined to larger, academic, urban hospitals, and centers with advanced HF facilities. Third, 
significant patient-level factors such as young age, female sex, admission with AMI, and 
cardiogenic shock were also associated with the use of PA catheters. Finally, HF patients 
undergoing PA catheter placement had higher in-hospital mortality and longer length of stay 
as compared with those without PA catheter placement; however, the excess associated 
mortality risk in the PA catheter group has attenuated substantially over time.
Our study findings provide important insights into the current practice patterns that may be 
driving the increase in PA catheter use over the past few years. While the total number of 
hospitals using any PA catheters in HF has declined significantly over the years, the volume 
of PA catheter use has increased disproportionately among large, urban, academic hospitals 
with facilities for advanced HF care. Furthermore, in risk-adjusted analysis, we observed 
that academic status and advanced HF management capabilities were independent hospital-
level predictors of increased PA catheter use in our study population. Taken together, our 
study findings suggest that the temporal increase in PA catheter use in the post-ESCAPE era 
may be related to its greater utilization at hospitals performing advanced HF therapies such 
as LVADs and heart transplantation and at other large academic centers, where a proportion 
of the PA catheter use may represent evaluation for such advanced therapies.
We also identified several patient-level characteristics that were independently associated 
with use of PA catheter. As expected, presence of class I indications such as cardiogenic 
shock and respiratory failure requiring mechanical intubation were associated with greater 
use of PA catheter. Furthermore, presence of AMI, acute kidney injury, and valvular heart 
disease were also independently associated with greater PA catheter use. This could be 
related to either more severe disease presentation and need for aggressive monitoring among 
these patients, or could represent diagnostic evaluation and uncertainty prior to consideration 
for further therapies in more advanced disease.
PA catheter use was associated with higher mortality risk in the overall study population in 
the propensity-matched analysis. However, there was a significant temporal decline in the 
excess mortality risk associated with PA catheter use such that it was not significant among 
patients treated between 2010–2012. While the improvement in HF mortality over time is 
consistent with previous reports in the literature and is likely related to the improvement in 
therapeutic options and quality of care over the past decade,26–29 the reason behind the 
relative improvement in the PA catheter group could not be ascertained. One potential 
explanation could be the increasing use of PA catheter among less sick patients as suggested 
by our prior analysis.9 Alternatively, higher use of PA catheters at large academic hospitals 
and advanced HF centers may have led to more effective utilization of the hemodynamic 
data by expert HF physicians to guide clinical management,30 and may have had an impact 
on patient outcomes.
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Our study findings have important clinical implications. The disproportionate increase in PA 
catheter use among academic centers with advanced HF capabilities coupled with the 
temporal decline in associated mortality risk points towards possibly a more judicious use of 
PA-catheter in the current clinical practice. In this regard, it is important to establish that the 
PA-catheter is a diagnostic tool, with its utility directly linked to the interpretation of the 
information it provides. As there has been an increase in potential advanced HF treatment 
options, PA-catheter use has become more prevalent, functioning as an adjunct for these 
advanced therapies, both during the short-term,11, 31 and long-term management of HF.32, 33 
Thus, PA-catheter use, may be providing data that, when used in conjunction with novel 
treatment options, provides benefit rather than harm for patients.
The findings of our study should be interpreted in light of some limitations. First, because of 
reliance on ICD-9-CM codes, we were unable to determine the physician perceived 
indication for PA catheter use and indirectly assessed that information from the documented 
discharge diagnoses. Moreover, the lack of information on the duration a PA catheter was 
left in situ precluded an indirect assessment of PA catheter use for diagnostic vs. a 
monitoring indication. Second, data regarding cause of death and procedural complications 
are not consistently recorded in the NIS, which makes it difficult to determine whether 
patients died as a result of underlying illness or a complication from the PA catheter use. 
While procedural complications were identified using ICD-9 codes, these codes for 
procedural complications have not been independently validated, and may underrepresent 
true complication rates. Third, as discussed previously, although we used a matched 
propensity score design to account for indication bias and our matching algorithm was 
successful in achieving covariate balance, important clinical variables that may be predictors 
of outcomes, as well as receipt of PA catheter use, were not available and these findings may 
be subject to confounding. Hence, the findings of our study represent associations and do not 
imply causation. Fourth, because of the administrative nature of data, we were unable to 
distinguish comorbidities from complications of hospitalization. Fifth, it is not possible to 
track patients longitudinally after discharge in NIS and readmissions will be counted as 
separate admissions. However, burden of HF hospitalizations has been assessed in the NIS 
using our current approach and correlates with resource utilization in HF, regardless of the 
ability to track individual patients.
In conclusion, in this study of US adults hospitalized with HF we observed significant 
hospital-level variation in use of PA catheterization, along with greater increase in use over 
time among large, academic hospitals, and advance HF centers. Furthermore, there was a 
significant decline in mortality risk associated with PA catheter over time in our study 
population.
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Clinical Perspective
Pulmonary artery (PA)-catheters have been used for invasive bedside hemodynamic 
monitoring in heart failure (HF) both to guide treatment decisions and to evaluate the 
hemodynamic responses to various therapies. Despite guideline recommendations 
advising limited use, there has been a significant increase in the use of PA-catheters in 
HF in the United States in recent years. In the present study, we found that there is 
substantial hospital-level variability in trends in the utilization of PA catheterization in 
HF. The recent increase in PA catheterization in HF is largely driven by increasing 
volume at fewer hospitals overrepresented by large, academic hospitals with advanced 
HF capabilities. While HF patients undergoing PA catheter placement had higher in-
hospital mortality compared with those without PA catheter placement, the excess 
associated mortality risk in the PA-catheter group has attenuated substantially over time. 
The disproportionate increase in PA-catheter use among academic centers with advanced 
HF capabilities coupled with the temporal decline in associated mortality risk points 
towards possibly a more judicious use of PA-catheter in the current clinical practice. In 
this regard, it is important to establish that the PA-catheter is a diagnostic tool, with its 
utility directly linked to the interpretation of the information it provides. As there has 
been an increase in potential advanced HF treatment options, PA-catheter use has become 
more prevalent, potentially functioning as an adjunct for these advanced therapies.
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Figure 1. 
Number of hospitals using PA catheterization in HF patients by study-year.
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Figure 2. 
Trends in PA catheter utilization in HF by hospital characteristics (A) hospital bedsize, (B) 
urban vs. rural location, (C) teaching status, and (D) advanced heart failure (HF) facilities.
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Figure 3. 
Multivariable predictors of PA catheter use.
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Figure 4. 
Trends in mortality in patients with PA catheterization in HF, (A) overall, and (B) risk-
adjusted odds ratios for mortality in propensity-matched analysis in different temporal 
cohorts.
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Table
Differences in characteristics for patients with and without use of pulmonary artery (PA) catheter in heart 
failure at hospitals using at least 1 PA catheter in HF in a given year
Characteristics* PA- catheter used No PA-catheter used P-value
Estimated number – N (S.D.) 75,209 (3276) 8,279,175 (175,167)
Patient characteristics
Mean Age (SEM) 64.8 (0.3) 72.5 (0.1) <0.0001
Age ≥ 65 year (%) 54.2 (0.9) 73.0 (0.4) <0.0001
Female Sex 40.8 (0.6) 52.6 (0.1) <0.0001
Race 0.34
  White 51.4 (1.7) 52.7 (0.9)
  Black 15.7 (0.9) 16.2 (0.6)
  Others 9.6 (0.6) 9.9 (0.4)
  Missing/Unknown 23.3 (2.1) 21.2 (1.0)
Secondary cardiovascular discharge diagnoses
Cardiogenic shock 9.3 (0.4) 0.4 (0.0) <0.0001
AMI 5.6 (0.2) 3.1 (0.0) <0.0001
CAD 48.6 (0.5) 52.3 (0.2) <0.0001
Cardiac arrest 3.2 (0.2) 0.7 (0.0) <0.0001
Cerebrovascular disease 3.6 (0.2) 4.5 (0.0) <0.0001
Arrhythmia 50.3 (0.6) 41.7 (0.3) <0.0001
Comorbid Conditions
Hypertension 56.4 (0.8) 68.3 (0.3) <0.0001
Diabetes Mellitus 37.1 (0.5) 42.2 (0.2) <0.0001
Dyslipidemia 26.4 (0.6) 27.4 (0.3) 0.0012
Cancer 7.8 (0.2) 10.1 (0.1) <0.0001
COPD 24.7 (0.5) 29.2 (0.2) <0.0001
Pneumonia 12.5 (0.4) 9.4 (0.1) <0.0001
Chronic kidney disease 22.7 (0.8) 19.8 (0.3) <0.0001
Acute kidney injury 30.5 (0.8) 11.6 (0.2) <0.0001
Liver disease 10.8 (0.3) 4.8 (0.1) <0.0001
Fluid/electrolyte disorder 33.6 (0.6) 22.5 (0.2) <0.0001
Anemia 23.9 (0.6) 25.4 (0.2) 0.0051
Coagulation disorder 7.7 (0.3) 3.3 (0.0) <0.0001
Tobacco abuse 9.0 (0.4) 8.0 (0.2) 0.005
Charlson Comorbidity Index 1.36 1.07 <0.0001
Past history
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Characteristics* PA- catheter used No PA-catheter used P-value
Prior myocardial infarction 11.1 (0.3) 11.6 (0.2) 0.17
Prior CABG 11.5 (0.3) 14.4 (0.1) <0.0001
Reported complications
Iatrogenic pneumothorax 0.4 (0.1) 0.1 (0.0) <0.0001
Bleeding 1.0 (0.1) 0.2 (0.0) <0.0001
Procedures
Vasopressor use 1.6 (0.2) 0.2 (0.0) <0.0001
Mechanical ventilation 20.7 (0.6) 4.9 (0.1) <0.0001
Elective admission 15.3 (0.8) 7.4 (0.2) <0.0001
Patient outcomes
Disposition <0.0001
  Home or self-care 48.3 (0.7) 57.2 (0.3)
  Short term hospital 6.4 (0.3) 2.9 (0.1)
  Skilled care facility 11.9 (0.4) 17.8 (0.2)
  Home health care 19.7 (0.6) 17.4 (0.2)
  Missing/AMA 0.6 (0.1) 1.2 (0.0)
  Died 13.1 (0.4) 3.4 (0.0)
Length of stay (days – mean ± SEM) 9.9 (0.1) 5.1 (0.0) <0.0001
Unadjusted mortality 13.1 (0.4) 3.4 (0.0) <0.0001
*
Represents percentages with the corresponding standard errors in parenthesis, unless otherwise specified
Abbreviations: SD – standard deviation, SEM – standard error of mean, C.I. – confidence interval, AMI - acute myocardial infarction, CAD - 
coronary artery disease, CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease, AMA – against medical advice
P values for positive trends, unless otherwise stated
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